---
layout: default
title: Cefetamet
parent: 僅模型預測 (L5)
nav_order: 154
evidence_level: L5
indication_count: 10
---

# Cefetamet
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cefetamet: From Bacterial Infections to Rheumatoid Arthritis

## One-Sentence Summary

Cefetamet is a third-generation cephalosporin antibiotic originally developed for the treatment of bacterial infections, including respiratory and urinary tract infections.
The TxGNN model predicts it may be effective for **Rheumatoid Arthritis** (top-ranked among 10 predicted indications),
however, **no clinical trials** and **no publications** currently support any of the 10 predicted indications — all evidence levels are L5.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Bacterial infections (3rd-generation cephalosporin antibiotic; no India/CDSCO approvals on record) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 97.99% |
| Evidence Level | L5 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Cefetamet belongs to the third-generation cephalosporin class — a group of broad-spectrum β-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Its oral prodrug form, cefetamet pivoxil, was historically used for community-acquired respiratory and urinary tract infections.

Cephalosporins have theoretical indirect pathways that could conceivably touch rheumatoid arthritis biology: some β-lactam antibiotics have shown weak NF-κB inhibitory activity in vitro, and there are known connections between infectious triggers (e.g., *Proteus mirabilis*, periodontal pathogens) and synovitis in RA. Eradication of such infections could, in theory, reduce antigen-driven joint inflammation. Cephalosporins may also modulate gut microbiota composition, with downstream effects on systemic immune tone.

However, these mechanistic links are highly speculative for Cefetamet specifically. No clinical or animal study has demonstrated anti-inflammatory efficacy for Cefetamet or any cephalosporin in RA. The TxGNN high score most likely reflects a shared comorbidity pathway ("infection → immune activation → arthritis") embedded in the knowledge graph, rather than a direct therapeutic mechanism. Notably, the same pattern of zero supporting evidence appears across all 10 top-ranked predictions — ranging from osteoarthritis to rare skeletal dysplasias — which further suggests that the scores here reflect knowledge-graph topological proximity rather than genuine repurposing potential.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All 10 TxGNN-predicted indications for Cefetamet are rated L5 with zero supporting clinical trials or literature, the mechanistic links are highly speculative or implausible (several top predictions involve rare monogenic skeletal dysplasias entirely unrelated to antibiotic mechanisms), and Cefetamet has no regulatory history in India.

**To proceed, the following is needed:**

- **MOA data**: Retrieve full DrugBank entry (DB13504) to confirm mechanism, targets, and any known off-target activity
- **CDSCO regulatory review**: Obtain Indian package insert or SmPC equivalent to assess approved indications, warnings, and contraindications before any safety evaluation can proceed
- **Mechanistic plausibility screen**: Conduct a structured literature review on β-lactam antibiotics and inflammatory arthritis (NF-κB, gut microbiome, infection-driven synovitis) to determine whether a credible hypothesis can be constructed
- **KG bias assessment**: Investigate whether the high TxGNN scores across diverse, mechanistically unrelated indications (RA, skeletal dysplasias, hemoglobinopathies) indicate a systematic knowledge-graph artefact for this drug node — if so, de-prioritise Cefetamet from the repurposing pipeline
- **In vitro pilot** (only if the above steps identify a plausible target): Test anti-inflammatory activity in relevant cell models (e.g., macrophage NF-κB reporter, fibroblast-like synoviocyte assay) before committing to animal or clinical studies
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

